BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19760609)

  • 1. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.
    Wegert J; Wittmann S; Leuschner I; Geissinger E; Graf N; Gessler M
    Genes Chromosomes Cancer; 2009 Dec; 48(12):1102-11. PubMed ID: 19760609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canonical WNT signalling determines lineage specificity in Wilms tumour.
    Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
    Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
    Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
    Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and analysis of mutations in WTX and WT1 genes in peripheral blood and tumor tissue of children with Wilms' tumor.
    Wang H; Shen Y; Sun N; Jiang YP; Li ML; Sun L
    Chin Med J (Engl); 2012 May; 125(10):1733-9. PubMed ID: 22800892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.
    Ruteshouser EC; Robinson SM; Huff V
    Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
    Fukuzawa R; Heathcott RW; More HE; Reeve AE
    J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children.
    Haruta M; Arai Y; Watanabe N; Fujiwara Y; Honda S; Ohshima J; Kasai F; Nakadate H; Horie H; Okita H; Hata J; Fukuzawa M; Kaneko Y
    Cancer Sci; 2012 Jun; 103(6):1129-35. PubMed ID: 22409817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
    Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
    Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.
    Phelps HM; Al-Jadiry MF; Corbitt NM; Pierce JM; Li B; Wei Q; Flores RR; Correa H; Uccini S; Frangoul H; Alsaadawi AR; Al-Badri SAF; Al-Darraji AF; Al-Saeed RM; Al-Hadad SA; Lovvorn Iii HN
    World J Pediatr; 2018 Dec; 14(6):585-593. PubMed ID: 30155617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries?
    Corbin M; de Reyniès A; Rickman DS; Berrebi D; Boccon-Gibod L; Cohen-Gogo S; Fabre M; Jaubert F; Faussillon M; Yilmaz F; Sarnacki S; Landman-Parker J; Patte C; Schleiermacher G; Antignac C; Jeanpierre C
    Genes Chromosomes Cancer; 2009 Sep; 48(9):816-27. PubMed ID: 19530245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.
    Rivera MN; Kim WJ; Wells J; Driscoll DR; Brannigan BW; Han M; Kim JC; Feinberg AP; Gerald WL; Vargas SO; Chin L; Iafrate AJ; Bell DW; Haber DA
    Science; 2007 Feb; 315(5812):642-5. PubMed ID: 17204608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene.
    Han M; Rivera MN; Batten JM; Haber DA; Dal Cin P; Iafrate AJ
    Genes Chromosomes Cancer; 2007 Oct; 46(10):909-13. PubMed ID: 17620295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WTX mutations can occur both early and late in the pathogenesis of Wilms tumour.
    Fukuzawa R; Holman SK; Chow CW; Savarirayan R; Reeve AE; Robertson SP
    J Med Genet; 2010 Nov; 47(11):791-4. PubMed ID: 20679664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathology, genetics and cytogenetics of Wilms' tumour.
    Md Zin R; Murch A; Charles A
    Pathology; 2011 Jun; 43(4):302-12. PubMed ID: 21516053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
    Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
    Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer. Converging on beta-catenin in Wilms tumor.
    Nusse R
    Science; 2007 May; 316(5827):988-9. PubMed ID: 17510350
    [No Abstract]   [Full Text] [Related]  

  • 19. Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target.
    Pode-Shakked N; Harari-Steinberg O; Haberman-Ziv Y; Rom-Gross E; Bahar S; Omer D; Metsuyanim S; Buzhor E; Jacob-Hirsch J; Goldstein RS; Mark-Danieli M; Dekel B
    Oncogene; 2011 Apr; 30(14):1664-80. PubMed ID: 21472018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WT1-Mutant Wilms Tumor Progression Is Associated With Diverting Clonal Mutations of CTNNB1.
    Duhme C; Busch M; Heine E; de Torres C; Mora J; Royer-Pokora B
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e180-e183. PubMed ID: 31876779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.